Bliss GVS

Mumbai, India Founded: 1984 • Age: 42 yrs Listed
Pharmaceutical products including suppositories and pessaries are manufactured.
Request Access
Report Incorrect Data
Page last updated

About Bliss GVS

Bliss GVS is a publicly listed company based in Mumbai (India) founded in 1984. Pharmaceutical products including suppositories and pessaries are manufactured. The company has 1,280 employees. Bliss GVS has completed 2 acquisitions, including EcoRich Cosmetic India and Kremoint Pharma. Its website blissgvs.com draws about 11 thousand monthly visits. Its Indian entity Bliss Gvs Pharma Limited reported revenue of ₹1,001 Cr. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.

Company details

Founded in 1984 and based in Mumbai, India, operations are focused on pharmaceutical manufacturing within the healthcare sector. A range of dosage forms is produced, such as capsules, creams, gels, ointments, tablets, injections, liquids, and pessaries. Contract research and manufacturing services are provided, alongside other items like balms, nasal inhalers, and over-the-counter products.

  • Headquarters Mumbai, India
  • Employees 1,280
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website blissgvs.com
  • Social LinkedIn
  • Legal Name Bliss Gvs Pharma Limited
Operational Areas
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹6,837 Cr

    BLISSGVS · NSE

  • Share Price
    ₹623.35

    -3.01% today

  • Revenue
    ₹927 Cr

    FY 2025-26 · +14.5% YoY

  • EBITDA
    ₹162 Cr

    Margin 17.4%

  • Net Profit
    ₹132 Cr

    FY 2025-26 · +56.1% YoY

  • P/E (TTM)
    47.3x

    P/B 5.5x

  • ROE
    12.0%

    ROCE 17.0%

  • Debt / Equity
    0.05

    Interest cover 9.4x

  • Employee Count
    1,280
  • Investments & Acquisitions
    EcoRich Cosmetic India

    & 1 more

Board of directors of Bliss Gvs Pharma Limited (Bliss GVS)

Bliss Gvs Pharma Limited is the primary company behind Bliss GVS. The board of Bliss Gvs Pharma Limited currently have 8 directors; the longest-serving is Shruti Vishal Rao, appointed in 2006. 16 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Shruti Vishal Rao
DIN 00731501
Whole-time director27 Jul 200620 yrs 2 moBliss Gvs Pharma Limited
Vibha Gagan Sharma
DIN 02307289
Whole-time director29 Jul 200818 yrs 2 moBliss Gvs Pharma Limited
Santosh Laxman Parab
DIN 01622988
Director24 May 201610 yrs 5 moBliss Gvs Pharma Limited
Aditi Himanshu Bhatt
DIN 07144131
Company Secretary09 Aug 20188 yrs 2 moBliss Gvs Pharma Limited
Shilpa Bhatia
DIN 08695595
Director11 Feb 20206 yrs 8 moBliss Gvs Pharma Limited
Deepak Bhalchandra Sawant
DIN 06564262
CFO24 Aug 20233 yrs 2 moBliss Gvs Pharma Limited
Nandkumar Kashinath Chodankar
DIN 02736718
Director22 Jun 20242 yrs 4 moBliss Gvs Pharma Limited
Narsimha Shibroor Kamath
DIN 00140593
CEO10 Oct 20251 yrBliss Gvs Pharma Limited

People of Bliss GVS

65 people are tracked at Bliss GVS (10 in leadership, 5 in board & advisors, 50 in team); the tracked headcount is 1,280.

NameRoleGroup
Gagan Harsh Sharma
Managing DirectorLeadership
Anandarup Datta
Head R&dLeadership
Hitesh Thakar
Country Head, Sales & Marketing, KenyaLeadership
Vineetha Nambiar
Head HR - Corporate, R&d And InternationalLeadership
Dr. Preeti Dali
Head Of Project Management OfficeLeadership
Amol Thorat
Head Of ProductionLeadership
Amar Pawar
Vice President - Technical OperationsLeadership
Rajendra Bachhav
Associated Vice PresidentLeadership
Yashwant Pawar
Head Of Learning And DevelopmentLeadership
Jayesh C.
Sr. General Manager, International BusinessLeadership
Shilpa Bhatia
Independent DirectorBoard & advisors
Santosh Parab
Independent DirectorBoard & advisors
Vibha Gagan Sharma
Whole-Time DirectorBoard & advisors
S. R. Vaidya
ChairmanBoard & advisors
Shruti Vishal Rao
Whole-Time DirectorBoard & advisors
Sumit Gaikar
Business AnalystTeam
Anish Singh
DGM - Finance & AccountsTeam
Pankaj Shinde
Formulation ManagerTeam
Amruta Dhuri
Human Resources AssistantTeam
Shilpa Ambastha
Manager R&d AnalyticalTeam

45 more people are available in the full profile.

Premium access

Complete people profiles for Bliss GVS

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Bliss GVS

Bliss GVS is a publicly listed company on the NSE with ticker symbol BLISSGVS in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date31 Oct 1985
  • Listed onBSE: 506197
  • Listed entityBliss GVS Pharma Limited
  • Exchange sectorHealth technology
  • ISININE416D01022
  • Share price₹660.70 (-1.54% on the day) · 2026-10-14
  • Market capitalisation₹7,136 Cr
  • Price to earnings52.4
  • EPS (diluted, trailing year)₹12.61
  • Dividend yield0.22%
  • Volume (last session)74,885

Financials of Bliss GVS

Exchange-reported figures of Bliss Gvs Pharma Limited, the listed company behind Bliss GVS (NSE: BLISSGVS).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹927 Cr
+14.5% YoY
EBITDA
₹162 Cr
+27.5% YoY
Profit After Tax
₹132 Cr
+56.1% YoY
Net Worth
₹1,193 Cr
+13.6% YoY
Total Assets
₹1,265 Cr
+6.8% YoY
Total Debt
₹21.75 Cr
-75.3% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue927810770752747577689
Revenue growth+14.5%+5.1%+2.5%+0.6%+29.5%-16.3%-
EBITDA16212712111744.74107110
EBITDA margin+17.4%+15.7%+15.8%+15.6%+6.0%+18.5%+16.0%
Profit before tax19012611710654.16104129
Net profit13284.4995.8670.6435.4368.53106
Net profit margin+14.2%+10.4%+12.5%+9.4%+4.7%+11.9%+15.4%
EPS (₹)12.218.007.216.801.456.649.43
Balance sheet
Total assets1,2651,1841,1061,022957952879
Net worth1,1931,050967884819808736
Total debt21.7588.1099.84102109122126
Cash & bank167213216103178145103
Net working capital718707708558626649625
Cash flow
Cash from operations13910610334.3113563.9746.70
Cash from investing(38.18)(75.49)(83.34)(6.36)(103)(45.38)(40.09)
Cash from financing(89.21)(30.20)(20.89)(24.94)(23.73)(20.80)(6.30)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue286257218244207198210218
Revenue growth (YoY)+37.7%+29.8%+3.7%+12.3%+13.0%---
Other income9.6011.1918.468.4635.4512.0715.275.04
EBITDA76.4044.4432.2743.4841.3321.0929.7941.48
EBITDA margin+26.8%+17.3%+14.8%+17.8%+19.9%+10.7%+14.2%+19.1%
Depreciation9.948.678.358.268.208.047.556.98
Interest0.582.011.493.045.471.681.083.83
Profit before tax75.4844.9540.8940.6463.1123.4436.4335.71
Tax24.117.9516.1212.0418.746.7910.6210.01
Net profit51.3737.0024.7728.6044.3716.6525.8125.70
EPS (₹)4.653.282.142.544.041.462.272.29
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue730667605598636466442
Revenue growth+9.4%+10.2%+1.2%-6.0%+36.7%+5.3%-
EBITDA13291.5866.0990.1510991.46100
EBITDA margin+18.1%+13.7%+10.9%+15.1%+17.2%+19.7%+22.7%
Profit before tax13394.1770.2611612691.19122
Net profit98.1369.1176.1185.2290.5967.5391.81
Net profit margin+13.5%+10.4%+12.6%+14.2%+14.2%+14.5%+20.8%
EPS (₹)9.166.554.848.218.946.548.95
Balance sheet
Total assets1,1801,1311,0691,020942850778
Net worth1,1551,059988937851756683
Total debt13.2367.7277.5080.5789.9191.8493.09
Cash & bank11117116984.6114912086.62
Net working capital662676691614662588572
Cash flow
Cash from operations12397.2182.1743.8111466.9763.22
Cash from investing(51.30)(77.97)(65.84)(12.97)(92.28)(61.62)(60.14)
Cash from financing(75.37)(26.56)(20.76)(26.05)(12.62)(11.67)(5.83)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue222212165190163156180183
Revenue growth (YoY)+35.7%+35.6%-8.3%+4.2%+9.7%---
Other income8.769.6610.2313.5910.599.3611.668.35
Total expenses170167140160131142154157
EBITDA51.8744.1524.3430.2732.7613.7325.7325.38
EBITDA margin+23.4%+20.9%+14.8%+15.9%+20.1%+8.8%+14.3%+13.9%
Depreciation9.037.847.807.697.687.436.966.39
Interest0.391.811.482.715.111.300.673.45
Profit before tax51.2144.1625.2933.4630.5614.3629.7623.89
Tax12.5911.746.688.669.512.918.726.84

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 24 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue286257218244207198210218
Revenue growth (YoY)+37.7%+29.8%+3.7%+12.3%+13.0%---
Other income9.6011.1918.468.4635.4512.0715.275.04
EBITDA76.4044.4432.2743.4841.3321.0929.7941.48
EBITDA margin+26.8%+17.3%+14.8%+17.8%+19.9%+10.7%+14.2%+19.1%
Depreciation9.948.678.358.268.208.047.556.98
Interest0.582.011.493.045.471.681.083.83
Profit before tax75.4844.9540.8940.6463.1123.4436.4335.71
Tax24.117.9516.1212.0418.746.7910.6210.01
Net profit51.3737.0024.7728.6044.3716.6525.8125.70
EPS (₹)4.653.282.142.544.041.462.272.29
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue927810770752747577689
Revenue growth+14.5%+5.1%+2.5%+0.6%+29.5%-16.3%-
Other income73.5336.4928.7417.7931.4920.2239.19
Total expenses766683649634703471579
Employee cost13611295.5886.1776.1568.0953.69
EBITDA16212712111744.74107110
EBITDA margin+17.4%+15.7%+15.8%+15.6%+6.0%+18.5%+16.0%
Depreciation33.4829.4226.3818.6717.3317.2312.59
Interest12.018.126.9110.364.745.517.57
Profit before tax19012611710654.16104129
Tax54.8635.3935.2929.3431.0430.1533.72
Net profit13284.4995.8670.6435.4368.53106
Net profit margin+14.2%+10.4%+12.5%+9.4%+4.7%+11.9%+15.4%
EPS (₹)12.218.007.216.801.456.649.43
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.5810.5410.4710.4210.3710.3110.31
Reserves & surplus1,1821,040957873808798725
Shareholders' funds (net worth)1,1931,050967884819808736
Minority interest38.8641.4735.7933.5327.7619.6614.76
Secured loans2.9370.9762.5671.3668.3197.64104
Unsecured loans18.8217.1337.2830.5441.0824.2622.50
Total debt21.7588.1099.84102109122126
Total liabilities1,2651,1841,1061,022957952879
Assets
Gross block608532468459344286277
Net block459406370379281234242
Capital work in progress6.0520.717.832.8022.152.390.00
Investments4.974.384.177.802.390.010.02
Inventories15112611810312498.9376.92
Sundry debtors517439404385393464548
Cash & bank balances167213216103178145103
Loans & advances11045.9971.9010182.6457.9144.37
Total current assets945824810692777765773
Total current liabilities227117102135150116147
Net working capital718707708558626649625
Total assets1,2651,1841,1061,022957952879
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash23.8223.5925.0121.9913.1315.3415.04
Net cash from operating activities13910610334.3113563.9746.70
Net cash from investing activities(38.18)(75.49)(83.34)(6.36)(103)(45.38)(40.09)
Net cash from financing activities(89.21)(30.20)(20.89)(24.94)(23.73)(20.80)(6.30)
Net change in cash11.320.23(1.42)3.028.85(2.21)0.30
Closing cash167213216103178145103
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+14.5%+5.1%+2.5%+0.6%+29.5%-16.3%-
EBITDA growth+27.5%+4.3%+3.5%+162.2%-58.1%-3.0%-
PBT growth+50.9%+7.5%+10.2%+95.9%-48.0%-19.3%-29.1%
Net income growth+56.1%-11.9%+35.7%+99.4%-48.3%-35.5%-
Revenue CAGR (3Y)+7.3%+2.7%+10.1%+2.9%-6.0%-10.9%-4.8%
EBITDA CAGR (3Y)+11.3%+41.5%+4.4%+2.2%-34.3%-13.2%-18.5%
Profitability & leverage
Net income margin+14.5%+11.2%+10.6%+10.2%+3.1%+12.8%+13.8%
Return on capital employed+17.0%+12.1%+14.8%+12.1%+14.2%+12.2%+16.9%
Return on net worth+12.0%+9.0%+11.0%+9.0%+5.4%+9.6%+13.8%
Debt / equity0.050.090.110.120.140.160.17
Long-term debt / equity0.020.040.050.040.040.050.05
Interest cover9.388.357.2710.5017.296.167.78
Efficiency & per share
Fixed asset turnover1.631.621.661.872.372.053.08
Inventory turnover6.716.636.956.626.716.568.94
Debtors turnover1.941.921.951.931.751.141.37
EPS (₹)12.218.007.216.801.456.649.43
Dividend per share (₹)0.500.500.500.500.500.500.50
Book value per share (₹)112.7699.6892.3884.8778.9778.3671.32
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue222212165190163156180183
Revenue growth (YoY)+35.7%+35.6%-8.3%+4.2%+9.7%---
Other income8.769.6610.2313.5910.599.3611.668.35
Total expenses170167140160131142154157
EBITDA51.8744.1524.3430.2732.7613.7325.7325.38
EBITDA margin+23.4%+20.9%+14.8%+15.9%+20.1%+8.8%+14.3%+13.9%
Depreciation9.037.847.807.697.687.436.966.39
Interest0.391.811.482.715.111.300.673.45
Profit before tax51.2144.1625.2933.4630.5614.3629.7623.89
Tax12.5911.746.688.669.512.918.726.84
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue730667605598636466442
Revenue growth+9.4%+10.2%+1.2%-6.0%+36.7%+5.3%-
Other income43.7236.2233.5050.7735.3717.6837.00
Total expenses598576539508527374342
Employee cost12299.4282.5972.5465.0658.6144.02
EBITDA13291.5866.0990.1510991.46100
EBITDA margin+18.1%+13.7%+10.9%+15.1%+17.2%+19.7%+22.7%
Depreciation31.0227.0523.5215.1713.8513.768.83
Interest11.116.585.8110.064.324.196.62
Profit before tax13394.1770.2611612691.19122
Tax36.5925.2019.6230.2133.7323.6829.37
Net profit98.1369.1176.1185.2290.5967.5391.81
Net profit margin+13.5%+10.4%+12.6%+14.2%+14.2%+14.5%+20.8%
EPS (₹)9.166.554.848.218.946.548.95
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.5810.5410.4710.4210.3710.3110.31
Reserves & surplus1,1451,048978927841745673
Shareholders' funds (net worth)1,1551,059988937851756683
Secured loans0.0023.1045.8365.7164.6967.8771.49
Unsecured loans13.2344.6231.6714.8625.2223.9721.60
Total debt13.2367.7277.5080.5789.9191.8493.09
Total liabilities1,1801,1311,0691,020942850778
Assets
Gross block555478414386270212203
Net block420369331326225175180
Capital work in progress4.4020.587.832.8022.152.390.00
Investments18.6918.6918.6918.2618.2618.3018.31
Inventories11181.9489.4574.1590.1183.6860.57
Sundry debtors457429400399409349405
Cash & bank balances11117116984.6114912086.62
Loans & advances14883.9911417214312590.55
Total current assets826766772730792677643
Total current liabilities16489.4281.7211613088.5970.94
Net working capital662676691614662588572
Total assets1,1801,1311,0691,020942850778
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash6.8514.1718.6013.824.6711.0013.75
Net cash from operating activities12397.2182.1743.8111466.9763.22
Net cash from investing activities(51.30)(77.97)(65.84)(12.97)(92.28)(61.62)(60.14)
Net cash from financing activities(75.37)(26.56)(20.76)(26.05)(12.62)(11.67)(5.83)
Net change in cash(3.52)(7.32)(4.43)4.799.14(6.33)(2.75)
Closing cash11117116984.6114912086.62
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+9.4%+10.2%+1.2%-6.0%+36.7%+5.3%-
EBITDA growth+44.0%+38.6%-26.7%-17.5%+19.4%-8.7%-
PBT growth+41.7%+34.0%-39.3%-8.5%+38.6%-25.1%+1.4%
Net income growth+42.0%-9.2%-10.7%-5.9%+34.2%-26.5%-
Revenue CAGR (3Y)+6.8%+1.6%+9.2%+10.6%+14.3%+16.0%+8.3%
EBITDA CAGR (3Y)+13.5%-5.7%-10.3%-3.5%+5.5%+1.1%-0.3%
Profitability & leverage
Net income margin+13.3%+10.3%+8.4%+14.3%+14.6%+14.5%+20.9%
Return on capital employed+12.5%+9.2%+11.2%+12.8%+14.6%+11.7%+17.6%
Return on net worth+8.8%+6.7%+7.9%+9.6%+11.5%+9.4%+14.4%
Debt / equity0.040.070.080.100.110.130.13
Long-term debt / equity0.020.040.050.040.040.050.05
Interest cover11.0210.2013.6513.424.535.397.25
Efficiency & per share
Fixed asset turnover1.411.501.511.822.642.252.97
Inventory turnover7.577.797.407.297.326.457.66
Debtors turnover1.651.611.521.481.681.241.18
EPS (₹)9.166.554.848.218.946.548.95
Dividend per share (₹)0.100.500.500.500.500.500.50
Book value per share (₹)109.20100.4794.4189.9682.1273.2666.21

Investments & Acquisitions by Bliss GVS

Bliss GVS has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include EcoRich Cosmetic India and Kremoint Pharma.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
EcoRich Cosmetic India
Manufacturer of cosmetics and personal care products
ecorichcosmetic.comMumbai, India2013Apr 2018••••
Kremoint Pharma
Traditional pharmaceutical company manufacturing and marketing variety of finished dosage forms
kremointpharma.comThane, India1994Jun 2012••••
Premium access

Complete acquisition details for Bliss GVS

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Bliss GVS

4 dated milestones of Bliss GVS across 34 years, from founding to its latest funding, stage changes and deals.

  1. Founded Bliss GVS is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Acquisition Acquires Kremoint Pharma.
  4. Acquisition Acquires EcoRich Cosmetic India.

Web traffic of Bliss GVS

The website of Bliss GVS (blissgvs.com) receives about 10.6K visits a month and ranks #3,528,800 among all websites worldwide, #4,571 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    10.6K

    ▲ 84.2% vs previous month

  • Unique visitors
    2.2K

    per month

  • Global rank
    #3,528,800

    among all websites

  • Category rank
    #4,571

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Bliss GVS. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Megafine
megafine.in
100%
View details
Ciron
cironpharma.com
98%
2.4K#7,858,699View details
Sanofi India
sanofiindialtd.com
96%
View details
Elder Pharamaceuticals
elderindia.com
96%
View details
PharmaCompass
pharmacompass.com
93%
301.1K#186,920View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 11 similar websites and full traffic analytics for Bliss GVS

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 11 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Bliss GVS (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Inventia Healthcare
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 89.42 M962
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M5,180
Sun Pharma
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.21 B25,870
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Bliss Gvs

Surat-based Anupam Rasayan completes ₹1,750-cr acquisition of 48.2% in Bliss GVS Pharma - The HinduBusinessLine
Thehindubusinessline • 26 days ago
Anupam Rasayan completes Bliss GVS deal, targets Rs 4,000-crore integrated platform - The Economic Times
Economic Times • 26 days ago
Anupam Rasayan completes purchase of 48.2 pc stake in Bliss GVS Pharma for ₹1,750 cr - The HinduBusinessLine
Thehindubusinessline • 26 days ago
Anupam Rasayan Completes Acquisition of Bliss GVS Pharma
Chemical Industry Digest • 26 days ago
Augment Infrastructure Partners offloads Rs 1,096 crore Clean Max stake; Belgrave Investment Fund sells 4.67% stake in Electrosteel Castings
Moneycontrol • 27 days ago
BLISSGVS-BE: RS. 136.70 CRORES NSE BLOCK TRADE; FOR ~ 1,859,916 SHARES, AT RS. 735.00
Exchange Update • 27 days ago
Bliss GVS Pharma consolidated net profit rises 16.40% in the June 2026 quarter | Capital Market News - Business Standard
Business Standard • 2 months ago
BLISSGVS: Revenue and net profit rose year-over-year, with EPS at ₹4.08 and new director appointment approved
Quartr • 2 months ago
Bliss GVS Pharma June-Quarter Consol Net Profit 501 Million Rupees
Reuters • 2 months ago
Nova Vida acquires shares worth Rs 34 crore in Mumbai-based small cap pharma company
Moneycontrol • 3 months ago
Premium access

Complete news archive for Bliss GVS

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Bliss GVS

Bliss GVS was founded in 1984.

Bliss GVS is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Bliss GVS has 1,280 employees.

The primary company behind Bliss GVS, Bliss Gvs Pharma Limited, reported revenue of ₹1,001 Cr for FY 2026, up 14% year on year.

Founded in 1984 and based in Mumbai, India, operations are focused on pharmaceutical manufacturing within the healthcare sector. A range of dosage forms is produced, such as capsules, creams, gels, ointments, tablets, injections, liquids, and pessaries. Contract research and manufacturing services are provided, alongside other items like balms, nasal inhalers, and over-the-counter products.

Yes, Bliss GVS is publicly traded on NSE under the ticker symbol BLISSGVS.

Bliss GVS has made 2 acquisitions, including EcoRich Cosmetic India, and Kremoint Pharma.

Bliss GVS operates through Bliss Gvs Pharma Limited.

The legal entities of Bliss GVS currently have 8 directors, including Shruti Vishal Rao, Vibha Gagan Sharma, Shilpa Bhatia and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available